Bioimpedance and chronoamperometryas an adjunct to prostate-specific antigenscreening for prostate cancer

Cancer Management and Research

Volumn 3, Issue 1, 2011, Pages 109-116

  de Abreu, Darci Schiavon ^a  

^a Department of Urology   (Brazil)

Author keywords

Bioimpedance; Delta of conductivity; Electro interstitial; Prostate cancer screening

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; ISOPHANE INSULIN; METFORMIN; METOPROLOL TARTRATE; OMEPRAZOLE; PROSTATE SPECIFIC ANTIGEN; RANITIDINE; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ALGORITHM; AMPEROMETRY; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIGITAL RECTAL EXAMINATION; ELECTRIC CONDUCTIVITY; HUMAN; HUMAN TISSUE; IMPEDANCE; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

EID: 79957861225     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMR.S19291     Document Type: Article

References (20)

1. Wingo PA, Landis S, Ries LA. An adjustment of the 1997 estimatefor new prostate cancer cases. CA Cancer J Clin. 1997;47:239-242.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5-27.
3. US Bureau of the Census, Population Division. Resident population of theUnited States: Estimates, by age and sex. Washington, DC: US Bureauof the Census, Population Division, release PPL-91. Available at: http://www.census.gov/population/estimates/nation/intfile2-1.txt. AccessedMarch 21, 2011.
4. Catalona WJ, Smith DS, Ratliff TL. Measurement of prostate specificantigen in serum as a screening test for prostate cancer. N Engl J Med.1991;324:1156-1161.
5. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectalexamination and serum prostate specific antigen in the early detectionof prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290.
6. Arcangeli CG, Ornstein DK, Keetch DW, Andriole GL. Prostate specificantigen as a screening test for prostate cancer. The United Statesexperience. Urol Clin North Am. 1997;24:299-306.
7. Ko HW, Smith DG, Skura JP. In vitro measurements of brain edema withthe magnetic bio-impedance method. Presented at the annual conferenceof the IEEE Engineering in Medicine and Biology Society, Amsterdam,The Netherlands, October 31-November 3, 1996.
8. Kimura S, Morimoto T, Uyama T, Monden Y, Kinouchi Y, Iritani T. Application of electrical impedance analysis for diagnosis of a pulmonarymass. Chest. 1994;105:1679-1682.
9. Halter RJ, Schned A, Heaney J, Hartov A, Schutz S, Paulsen KD. Electricalimpedance spectroscopy of benign and malignant prostatic tissues. JUrol. 2008;179:1580-1586.
10. Mamalakis G, Kafatos A, Kalogeropoulos N, Andrikopoulos N, Daskalopulos G, Kranidis A. Prostate cancer vs hyperplasia: relationshipswith prostatic and adipose tissue fatty acid composition. ProstaglandinsLeukot Essent Fatty Acids. 2002 May-Jun;66 (5-6):467-477.Cole KS, Li CL, Bak AF. Electrical analogues for tissues. Exp Neurol.1969;24:459-473.
11. Grimmes S, Martinsen ØG. Electrolytics In Bioimpedance andBioelectricityBasics. San Diego, CA: Academic Press; 2000.
12. Cottrell FG. Application to the Cottrell equation to chronoamperometry. Z Physik Chem. 1902;42:385.
13. Gabriel S, Lau RW, Gabriel C. The dielectric properties of biologicaltissues: III. Parametric models for the dielectric spectrum of tissues.Phys Med Biol. 1966;41:2271-2293.
14. Svetec D, Thompson IM. PSA screening - current controversy. AnnOncol. 1998;9:1283-1288.
15. Godley PA. Prostate cancer screening: Promise and peril - a review.Cancer Detect Prev. 1999;23:316-324.
16. Scardino PT. Early detection of prostate cancer. Urol Clin North Am.1989;16:635-655.
17. Cochran WG. Sampling Techniques. 3rd ed. New York, NY: JohnWiley & Sons; 1977.
18. Zappa M, Ciatto S, Bonardi R, Mazzotta A. Overdiagnosis of prostatecarcinoma by screening: An estimate based on the results of the Florencescreening pilot study. Ann Oncol. 1998;9:1297-1300.
19. Alan W, Partin MD, Michael W, et al. Combination of Prostate-SpecificAntigen, Clinical Stage, and Gleason Score to Predict PathologicalStage of Localized Prostate Cancer. JAMA. May 14,1997;277(18):1445-1451.
20. Kishor Mistry, Greg Cable. Meta-Analysis of Prostate-Specific Antigenand Digital Rectal Examination as Screening Tests for ProstateCarcinoma. The Journal of the American Board of Family Practice. 2003;16:95-101.